Everything below concerns 肽类药物. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-24. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Upon arriving at 25,000 ft, students are removed from their oxygen supply two at a time, for around 2 to 3 minutes. During this time, they will be asked to complete simple tasks such as copying shapes on a piece of paper. They are asked during the time off oxygen how they feel. After being placed back on oxygen, they will understand how their judgement was impaired during the time that they were experiencing hypoxia. The training goes further with rapid decompression profiles, where the chamber is very rapidly ascended from 8,000 ft to 22,000 ft within 10 to 20 seconds, to simulate the loss of a cabin door. For fighter pilots this is done from an altitude of 25,000 ft to 43,000 ft within 5 seconds which simulates the loss of a fighter aircraft's canopy. Hypobaric chambers are also finding increasing use as a means of improving athletic performance. Since the human body adapts to extended mild hypoxia by increasing the quantity of red cells in the blood and this raises aerobic performance, athletes sleep in them as part of their training regimen. This has roughly the same effect as training in high altitudes, but the use of hypobaric chambers plays into the controversial issue of enhanced athletic performance. Mika LaVaque-Manty asks in his book, "Are hypobaric chambers, which simulate high-altitude conditions, a natural way to improve your body?" This hints that the hypobaric chambers use can be likened to blood doping and thus be deemed an unfair athletic advantage. This could lead to a ban on hypobaric chambers for athletic training.
=== Methylene blue value of fine aggregate === The methylene blue value is defined as the number of milliliters of standard methylene blue solution decolorized 0.1 g of activated carbon (dry basis). Methylene blue value reflects the amount of clay minerals in aggregate samples. In materials science, methylene blue solution is successively added to fine aggregate which is being agitated in water. The presence of free dye solution can be checked with a stain test on a filter paper.
== Functions == Some fusion proteins combine whole peptides and therefore contain all functional domains of the original proteins. However, other fusion proteins, especially those that occur naturally, combine only portions of coding sequences and therefore do not maintain the original functions of the parental genes that formed them. Many whole gene fusions are fully functional and can still act to replace the original peptides. Some, however, experience interactions between the two proteins that can modify their functions. Beyond these effects, some gene fusions may cause regulatory changes that alter when and where these genes act. For partial gene fusions, the shuffling of different active sites and binding domains have the potential to result in new proteins with novel functions.
=== Hydraulics === Liquid is the primary component of hydraulic systems, which take advantage of Pascal's law to provide fluid power. Devices such as pumps and waterwheels have been used to change liquid motion into mechanical work since ancient times. Oils are forced through hydraulic pumps, which transmit this force to hydraulic cylinders. Hydraulics can be found in many applications, such as automotive brakes and transmissions, heavy equipment, and airplane control systems. Various hydraulic presses are used extensively in repair and manufacturing, for lifting, pressing, clamping and forming.
=== Insect === The Drosophila melanogaster genome contains 29 serpin encoding genes. Amino acid sequence analysis has placed 14 of these serpins in serpin clade Q and three in serpin clade K with the remaining twelve classified as orphan serpins not belonging to any clade. The clade classification system is difficult to use for Drosophila serpins and instead a nomenclature system has been adopted that is based on the position of serpin genes on the Drosophila chromosomes. Thirteen of the Drosophila serpins occur as isolated genes in the genome (including Serpin-27A, see below), with the remaining 16 organised into five gene clusters that occur at chromosome positions 28D (2 serpins), 42D (5 serpins), 43A (4 serpins), 77B (3 serpins) and 88E (2 serpins). Studies on Drosophila serpins reveal that Serpin-27A inhibits the Easter protease (the final protease in the Nudel, Gastrulation Defective, Snake and Easter proteolytic cascade) and thus controls dorsoventral patterning. Easter functions to cleave Spätzle (a chemokine-type ligand), which results in toll-mediated signaling. As well as its central role in embryonic patterning, toll signaling is also important for the innate immune response in insects. Accordingly, serpin-27A also functions to control the insect immune response. In Tenebrio molitor (a large beetle), a protein (SPN93) comprising two discrete tandem serpin domains functions to regulate the toll proteolytic cascade. Serpins have been found in tick saliva, suppressing T lymphocyte production and inhibiting expression of TNF-α, IFN-γ, and IL-6.
Sources: en.wikipedia.org
== Early life and education == Arthur 'Blaine' Bowman was born in 1946 in Ogden, Utah, US. Around age 10, his family moved to Southern California, where he grew up. Bowman attended Brigham Young University in Provo, Utah in the physics program. As an undergraduate, he worked in the summer as an engineer at McDonnell Douglas, testing modules for the Apollo rocket. Bowman received his B.S. in physics in 1970. Next, Bowman worked as a product engineer at Motorola's Semiconductor Products Division in Phoenix, Arizona, where he became interested in business. He attended Stanford University's school of business from 1971 to 1973, receiving his M.B.A. in 1973. He then joined McKinsey & Company as a management consultant.
There may be flocculation in some gels, which may produce an unstable gel. The rheology of some gels are easily altered by environmental factors such as temperature and humidity, resulting in stricter storage requirements. Syneresis of the gel may occur during storage, causing the gel to shrink unpredictably or even dry out. The gelators may precipitate and salt out, and some drugs may degrade in gel formulation due to the other ingredients present in the formulation. Some additives and gelators added into the formulation may cause irritation problems, such as skin irritation, dermatitis or allergic conditions. The increased water content in gels increases the chances of bacterial or fungal attack, which may contaminate the gel, making it unsuitable for use. Considering the direct route of administration, drugs must be very small in size to have an effective plasma concentration for action. The particle size and other properties of the drug may also affect its absorption through the skin barrier, resulting in an unreliable effect.
For example, changes in farming practices such as the indoor raising of cattle and incineration or burial of cattle carcasses have reduced food availability for Eurasian griffon vultures. Shootings of birds, removal of nestlings from nests, and drug pollution have also contributed to declines in vulture populations.
== Recommendation == As of 2026, the WHO/EPI recommends universal vaccination against diphtheria, Haemophilus influenzae type B (Hib), Hepatitis B (HepB), human papillomavirus (HPV), measles, pertussis, pneumococcal disease, polio, Respiratory Syncytial Virus (RSV), rotavirus, rubella, and tetanus. High risk groups should also be given COVID-19 and seasonal influenza vaccines. There is also a list of more than 20 context-specific vaccine-preventable diseases for specific geographic areas and populations.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。